ロード中...
RAS-protein activation but not mutation status is an outcome predictor and unifying therapeutic target for high-risk acute lymphoblastic leukemia
Leukemias are routinely sub-typed for risk/outcome prediction and therapy choice using acquired mutations and chromosomal rearrangements. Down syndrome acute lymphoblastic leukemia (DS‐ALL) is characterized by high frequency of CRLF2‐rearrangements, JAK2‐mutations, or RAS‐pathway mutations. Intrigui...
保存先:
| 出版年: | Oncogene |
|---|---|
| 主要な著者: | , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Nature Publishing Group UK
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7843419/ https://ncbi.nlm.nih.gov/pubmed/33247204 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41388-020-01567-7 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|